MCM
NUVB icon

Moore Capital Management’s Nuvation Bio NUVB Stock Holding History

Moore Capital Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-50,000
Closed -$560K – 580
2020
Q3 		$560K Buy
+50,000
New +$540K 0.01% 316

Other funds holding NUVB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return

Moore Capital Management's NUVB Position: Q4 2020 in Review

Moore Capital Management sold out of Nuvation Bio (NUVB) in Q4 2020, closing a stake of 50,000 shares — an estimated $560K sold.

Moore Capital Management first reported a position in NUVB in Q3 2020 and held it in 1 quarter. The position peaked at $560K in Q3 2020. 33 funds tracked by Wall St. Rank hold NUVB as of Q4 2020.

  • Moore Capital Management reported no remaining Nuvation Bio position as of Q4 2020 after selling out during the quarter.
  • Moore Capital Management sold 50,000 Nuvation Bio shares in Q4 2020, an estimated $560K.
  • Moore Capital Management first reported a position in Nuvation Bio in Q3 2020 and held it in 1 quarter.
  • Moore Capital Management's Nuvation Bio position peaked at $560K in Q3 2020.
  • 33 funds tracked by Wall St. Rank held Nuvation Bio as of Q4 2020.

Based on Moore Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.